Literature DB >> 2161806

How to predict the immune status of poliovirus vaccinees? A comparison of virus neutralization at a very low serum dilution versus ELISA in a cohort of infants.

A Simhon1, A Lifshitz, Y Abed, E E Lasch, B Schoub, A Morag.   

Abstract

A cohort of children from Gaza was observed from birth to the age of one year. Blood specimens were collected at birth, before and after poliovirus vaccination and at one year of age. Poliovirus immunity before and after vaccination was assessed by ELISA and virus neutralization (NT). Positive predictive values for ELISA were between 81.5% and 90.8%. However, ELISA revealed a high frequency of false negatives, and unacceptably low negative predictive values between 28.6% and 55.4%. The history of poliovirus immunity in the cohort was further investigated by NT. A high level of seropositivity to poliovirus type 1 (PV-1) was found. In cord blood, 83.3% had a NT titre greater than or equal to 4 and 99.0% had a titre greater than or equal to 2. Similarly, by one year of age, 85.7% had a titre greater than or equal to 4 and 90.5% had a titre greater than or equal to 2. Seropositivity to PV-2 and PV-3 were slightly lower, ie 80.8% of children had a PV-2 titre greater than or equal to 4 and 75.4% had a PV-3 titre greater than or equal to 4. As for other developing areas, poliomyelitis eradication in Gaza will come about when universal vaccination fills all 'immunity gaps' and improved sanitation and housing reduces the endemicity of wild polioviruses.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2161806     DOI: 10.1093/ije/19.1.164

Source DB:  PubMed          Journal:  Int J Epidemiol        ISSN: 0300-5771            Impact factor:   7.196


  6 in total

1.  Evaluation of a poliovirus-binding inhibition assay as an alternative to the virus neutralization test.

Authors:  M M Herremans; J H Reimerink; A Ras; H G Van Der Avoort; T G Kimman; A M Van Loon; M A Conyn-Van Spaendonck; M P Koopmans
Journal:  Clin Diagn Lab Immunol       Date:  1997-11

2.  Inducing dose sparing with inactivated polio virus formulated in adjuvant CAF01.

Authors:  Jes Dietrich; Lars Vibe Andreasen; Peter Andersen; Else Marie Agger
Journal:  PLoS One       Date:  2014-06-23       Impact factor: 3.240

3.  Effect of HIV-exposure and timing of anti-retroviral treatment on immunogenicity of trivalent live-attenuated polio vaccine in infants.

Authors:  Shelina Moonsamy; Melinda Suchard; Shabir A Madhi
Journal:  PLoS One       Date:  2019-04-19       Impact factor: 3.240

4.  Neonatal vitamin A supplementation and immune responses to oral polio vaccine in Zimbabwean infants.

Authors:  James A Church; Sandra Rukobo; Margaret Govha; Marya P Carmolli; Sean A Diehl; Bernard Chasekwa; Robert Ntozini; Kuda Mutasa; Jean H Humphrey; Beth D Kirkpatrick; Andrew J Prendergast
Journal:  Trans R Soc Trop Med Hyg       Date:  2019-03-01       Impact factor: 2.184

5.  Serum and mucosal antibody responses to inactivated polio vaccine after sublingual immunization using a thermoresponsive gel delivery system.

Authors:  Jessica A White; Jeremy S Blum; Nancy A Hosken; Joshua O Marshak; Lauren Duncan; Changcheng Zhu; Elizabeth B Norton; John D Clements; David M Koelle; Dexiang Chen; William C Weldon; M Steven Oberste; Manjari Lal
Journal:  Hum Vaccin Immunother       Date:  2014       Impact factor: 3.452

6.  Immune responses to oral poliovirus vaccine in HIV-exposed uninfected Zimbabwean infants.

Authors:  James A Church; Sandra Rukobo; Margaret Govha; Marya P Carmolli; Sean A Diehl; Bernard Chasekwa; Robert Ntozini; Kuda Mutasa; Jean H Humphrey; Beth D Kirkpatrick; Andrew J Prendergast
Journal:  Hum Vaccin Immunother       Date:  2017-08-31       Impact factor: 3.452

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.